Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation
Recommended Citation
Lioutas VA, Goyal N, Katsanos AH, Krogias C, Zand R, Sharma VK, Varelas P, Malhotra K, Paciaroni M, Karapanayiotides T, Sharaf A, Chang J, Kargiotis O, Pandhi A, Palaiodimou L, Schroeder C, Tsantes A, Boviatsis E, Mehta C, Serdari A, Vadikolias K, Mitsias PD, Selim MH, Alexandrov AV, and Tsivgoulis G. Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation. J Neurol 2019
Document Type
Article
Publication Date
12-17-2019
Publication Title
Journal of neurology
Abstract
BACKGROUND: Every anticoagulation decision has in inherent risk of hemorrhage; intracerebral hemorrhage (ICH) is the most devastating hemorrhagic complication. We examined whether combining ischemic and hemorrhagic stroke risk in individual patients might provide a meaningful paradigm for risk stratification.
METHODS: We enrolled consecutive patients with anticoagulation-associated ICH in 15 tertiary centers in the USA, Europe and Asia between 2015 and 2017. Each patient was assigned baseline ischemic stroke and hemorrhage risk based on their CHA
RESULTS: We enrolled 357 patients [59% men, median age 76 (68-82) years]. 31% used non-vitamin K antagonist (NOAC). 191 (53.5%) patients had a favorable indication for anticoagulation prior to their ICH; 166 (46.5%) unfavorable. Those with unfavorable indication were younger [72 (66-80) vs 78 (73-84) years, p = 0.001], with lower CHA
CONCLUSIONS: In this anticoagulation-associated ICH cohort, baseline hemorrhagic risk exceeded ischemic risk in approximately 50%, highlighting the importance of careful consideration of risk/benefit ratio prior to anticoagulation decisions. The remaining 50% suffered an ICH despite excess baseline ischemic risk, stressing the need for biomarkers to allow more precise estimation of hemorrhagic complication risk.
PubMed ID
31848737
ePublication
ePub ahead of print
